BG Medicine down hard after Q2 earnings report

BG Medicine (BGMD -18%) takes a hit after reporting its Q2 earnings this morning.

Its net loss came in at $4.8M, a 25% reduction from the net loss reported in Q212.

The company expects FY13 revenue to range between $3.8M to $4M.

Operating cash burn for  FY13 will range from $15.5M to $16.5M and principal payments on its term loan to be $2.5M.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs